Poster Session : PS 0144 ; Neurology : Estimating Effi cacy of Active Hexose Correlated Compound as Immune Therapy for Patients Diagnosed with Pharmacoresistant Epilepsy = Poster Session : PS 0144 ; Neurology : Estimating Effi cacy of Active Hexose Correlated Compound as Immune Therapy for Patients Diagnosed with Pharmacoresistant Epilepsy

다국어 초록 (Multilingual Abstract)

Background: examination of clinical neuroimmune disorders of patients diagnosed with pharmacoresistant epilepsy, to estimate immune role in pathogenesis of the disease and effi cacy of immune therapy, Active Hexose Correlated Compound (AHCC) supplement, in particular. Methods: several children with unmoderate verifi ed resistant epilepsy were examined with clinico-paraclinic Methods: Immunologic methods included prelaboratory examination aimed at revealing clinical syndromes of secondary immunodefi ciency and laboratory examination with the purpose to identify multiple defects in the immune system. Immunologic examination was performed according to standard Methods: In order to determine immune status there were measured quantitative and functional indicators: 1) percentage of T- and B- lymphocytes in peripheral blood (total number of lymphocytes, percentage and absolute number of mature T-cells - CD3+, two basic subpopulations - helpers CD4+ and killers-suppressors CD8+; В-lymphocytes - CD20+; immunoregulatory balance - balance between CD4+ and CD8+; 2) concentration of serum immunoglobulin А, G, М (IgА, IgG, IgМ). All patients received combined treatment including baseline antiepileptic and immune therapy АНСС -2 i.d. during one month. Results: after AHCC intake patients had positive quantity changes of peripheral t-cell pool (CD3+), Т-helpers amount increase (CD4+) and 1,4 times more increase of T-suppressors/ killers (CD8+-lymphocytes). Due to CD4+ lymphocytes subset, current changes moved up immunoregulatory balance (CD4+/CD8+). 35% of clinical changes displayed frequency and intensity reduction of epileptic seizures, other patients had somatic health status and physiological functions improved. Conclusions: Mentioned before data demonstrate that patients with resistant epilepsy have signifi cant neuroimmune disorders. АНСС Immunotherapy improves immune status by increasing amount of Т-lymphocytes, regulate subset balance, activates phagocytes and humoral function. In addition, it decreases neuroimmunization by regulating amount of serum immunoglobulins. Such effect indicates reverse of autoimmune process which has pathobiological signifi cance in epileptogenesis.